Business, energy, technology, markets and global industry news from Business News Today

Keytruda

PharmaDeviceNews Keytruda
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Representative image of a modern pathology laboratory where automated PD-L1 cancer diagnostic testing is supporting faster immuno-oncology treatment decisions, reflecting Agilent Technologies’ expanded FDA approval for PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform.
Medical Devices & Diagnostics

Agilent wins FDA backing to move more Keytruda-linked PD-L1 testing onto Dako Omnis

Find out how Agilent’s expanded PD-L1 test approval could change automated cancer diagnostics and oncology lab workflows.

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Representative image of biotech research technology for chronic myeloid leukemia drug development, highlighting how Merck & Co.’s Terns Pharmaceuticals acquisition could sharpen the race for next-generation targeted oncology therapies.
Features & Analysis

Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight

Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.

Read More
Pharma & Biotech

Can Immutep Limited convert orphan designation into a credible late-stage oncology program?

FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.

Read More
KEYTRUDA and WELIREG deliver Phase 3 LITESPARK-022 win in adjuvant clear cell renal cell carcinoma, reshaping post-nephrectomy care
Pharma & Biotech

Merck’s KEYTRUDA plus WELIREG cuts recurrence risk in Phase 3 LITESPARK-022 trial for adjuvant clear cell renal cell carcinoma

KEYTRUDA plus belzutifan cuts recurrence risk in adjuvant RCC. Explore what LITESPARK-022 changes for kidney cancer treatment.

Read More
Representative image of a melanoma lesion under examination. Moderna and Merck’s 5-year data show their personalized mRNA cancer vaccine may significantly reduce recurrence in high-risk cases.
Pharma & Biotech

Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma

Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or

Read More
A representative image of bladder cancer treatment. As PADCEV and Keytruda show promise in transforming perioperative care, new platinum-free regimens are reshaping how muscle-invasive bladder cancer is managed.
Pharma & Biotech

PADCEV plus Keytruda meets survival endpoints in cisplatin-eligible bladder cancer patients

Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival

Read More